Adeia to Release Fourth Quarter 2024 Financial Results on February 18, 2025
16 janv. 2025 16h05 HE
|
Adeia Inc.
SAN JOSE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA) will announce its financial results for the fourth quarter ended December 31, 2024, on Tuesday, February 18, 2025,...
Adeia Announces Third Quarter 2024 Financial Results
07 nov. 2024 16h12 HE
|
Adeia Inc.
Signed 7 deals across multiple verticals in the third quarterBoard increased share repurchase authorization up to $200 millionFiled patent infringement litigation against DisneySigned a new...
Yuanyu Enterprise Management announces entry into an exclusive license agreement for its innovative matchmaking technology covering the UK and Europe
07 oct. 2024 08h00 HE
|
Connexa Sports Technologies Inc.
UK-based Eternity Technology Limited agrees to license Yuanyu’s matchmaking services for the emerging Love & Marriage sector.Agreement to generate more than $19 million in license income for YYEM...
Evaxion significantly expands vaccine development collaboration with MSD
26 sept. 2024 07h30 HE
|
Evaxion Biotech
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on...
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
12 sept. 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-4452)...
Adeia Renews Long-Term IP License Agreement with Liberty Global
08 juil. 2024 16h05 HE
|
Adeia Inc.
Adeia Renews Long-Term IP License Agreement with Liberty Global
Adeia Enters into Multi-Year IP License Agreement with X Corp.
01 juil. 2024 16h05 HE
|
Adeia Inc.
Adeia Enters into Multi-Year IP License Agreement with X Corp.
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
13 juin 2024 07h00 HE
|
BioRestorative Therapies, Inc
- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders – - ThermoStem® is an off-the-shelf...
Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio
30 janv. 2024 12h00 HE
|
Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
14 déc. 2023 09h28 HE
|
ITM Isotope Technologies Munich SE
ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens indication areas to...